Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.45% -0.19% 7.482M 2650.33
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0.00% 66.00% 1.682M Upgrade

Basic Info

Investment Strategy
The investment seeks to track the total return performance, before fees and expenses, of the NASDAQ Junior Biotechnology Index. The index is a rules-based index that consists of a portfolio of the stock of U.S.-listed small capitalization ("junior") companies screened from the universe of the NASDAQ Biotechnology Index. The fund will generally use a "replication" strategy to achieve its investment objective, meaning it will generally invest in all of the component securities of the index in the same approximate proportions as in the index. The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style --
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Technology
Fund Owner Firm Name Defiance ETFs
Prospectus Benchmark Index
NASDAQ Junior Biotechnology TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Anand Desai 1.33 yrs
Dustin Lewellyn 1.33 yrs
Ernesto Tong 1.33 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 36
1.682M
-4.455B Category Low
4.573B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of November 30, 2021

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of December 03, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2014
2015
2016
2017
2018
2019
2020
YTD
--
--
--
--
--
--
--
-13.27%
4.94%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
19.95%
33.83%
11.56%
-21.41%
21.08%
-9.53%
25.21%
26.01%
-0.17%
--
19.54%
6.26%
24.07%
-13.95%
24.73%
22.24%
-10.59%
--
5.25%
-36.63%
56.10%
-18.29%
63.81%
30.32%
-20.00%
--
--
--
--
--
--
--
--
As of December 07, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (12-7-21) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio --
Weighted Average Price to Book Ratio --
Weighted Median ROE --
Weighted Median ROA --
Forecasted Dividend Yield --
Forecasted PE Ratio --
Forecasted Price to Sales Ratio --
Forecasted Price to Book Ratio --
As of December 03, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth --
Forecasted Book Value Growth --
Forecasted Cash Flow Growth --
Forecasted Earnings Growth --
Forecasted Revenue Growth --
As of December 03, 2021

Asset Allocation

As of December 03, 2021.
Type % Net % Long % Short
Cash 0.00% Upgrade Upgrade
Stock 99.98% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 2 Holdings

Name % Weight Price % Change
PDL BioPharma Inc
99.99% -- --
Contra Restorbio Inc
0.01% -- --

News

Headline
Wire
Time (ET)
PR Newswire
10/22 16:00

Basic Info

Investment Strategy
The investment seeks to track the total return performance, before fees and expenses, of the NASDAQ Junior Biotechnology Index. The index is a rules-based index that consists of a portfolio of the stock of U.S.-listed small capitalization ("junior") companies screened from the universe of the NASDAQ Biotechnology Index. The fund will generally use a "replication" strategy to achieve its investment objective, meaning it will generally invest in all of the component securities of the index in the same approximate proportions as in the index. The fund is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style --
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Technology
Fund Owner Firm Name Defiance ETFs
Prospectus Benchmark Index
NASDAQ Junior Biotechnology TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Anand Desai 1.33 yrs
Dustin Lewellyn 1.33 yrs
Ernesto Tong 1.33 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (12-7-21) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio --
Weighted Average Price to Book Ratio --
Weighted Median ROE --
Weighted Median ROA --
Forecasted Dividend Yield --
Forecasted PE Ratio --
Forecasted Price to Sales Ratio --
Forecasted Price to Book Ratio --
As of December 03, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth --
Forecasted Book Value Growth --
Forecasted Cash Flow Growth --
Forecasted Earnings Growth --
Forecasted Revenue Growth --
As of December 03, 2021

Fund Details

Key Dates
Inception Date 8/3/2020
Last Annual Report Date 12/31/2020
Last Prospectus Date 4/30/2021
Attributes
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No

News

Headline
Wire
Time (ET)
PR Newswire
10/22 16:00